trending Market Intelligence /marketintelligence/en/news-insights/trending/hApTxgW9mGetL_UX2VC9Vw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Biogen to pay CAMP4 $15M upfront under pact to discover brain disease therapies

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Biogen to pay CAMP4 $15M upfront under pact to discover brain disease therapies

Biogen Inc. will pay CAMP4 Therapeutics Corp. $15 million upfront to use the privately held company's Gene Circuitry Platform under a collaboration to discover and develop therapies for neurological diseases.

Cambridge, Mass.-based CAMP4's Gene Circuitry Platform will be used to identify how to tweak the expression of disease-associated genes within the primary immune cells of the central nervous system called microglial cells, which are believed to play a role in many neurological and neurodegenerative diseases.

Under the agreement, Cambridge, Mass.-based Biogen will also reimburse CAMP4 for research activities and will have the option to select targets to advance to discovery, development and commercialization.

CAMP4 will be eligible to receive development and milestone payments of up to $96 million in addition to royalties for each of the initially selected targets and up to $173 million plus royalties for each additional target.

The companies will also explore other cell types of the central nervous system beyond microglial cells to potentially expand the number of neurological diseases that could be addressed.